The American Weight Loss Association is launching now to fill the clinical support gap the obesity and peptide therapy revolution has exposed. We are establishing the definitive education, standards, and certification framework for providers across every medication category — protecting providers, safeguarding patients, and bridging the gap between medication and care.
The missing layer: Manufacturers, discount platforms, and independent providers all supply medication. None provide the clinical support infrastructure patients need. That is what TAWLA builds.
Medication access is outpacing clinical support. Patients are receiving GLP-1 and peptide therapies through multiple channels — with inconsistent screening, monitoring, side-effect management, and follow-up. TAWLA is the first organized solution.
Tens of thousands of clinics, medical spas, weight loss centers, and telehealth platforms — plus discount platforms like Amazon, Cost Plus, and Trump RX — serve patients with zero clinical follow-up infrastructure.
Manufacturer direct, independent compounders, and discount platforms each supply medication. None provide the clinical support, monitoring, or follow-up that patients receiving obesity and peptide therapies genuinely need.
No national safety framework. No standardized monitoring. No organized follow-up. No education standards for providers. TAWLA builds all of it — serving every channel simultaneously.
TAWLA is the clinical support infrastructure this market has been missing. An independent education, standards, and certification platform serving providers in GLP-1 and peptide therapy across every distribution channel — for the first time.
View Partnership OptionsTwo powerful platforms — one established national organization, one targeted provider network — working together as the definitive home for GLP-1 clinical standards in America.
Thousands of clinics, medical spas, weight loss centers, and telehealth providers across the country are navigating cease-and-desist letters, regulatory ambiguity, and zero collective support. TAWLA provides the education, standards, and organized voice this community needs.
What Providers Are Facing Right Now
Manufacturers have been sending C&D letters to providers using compounded GLP-1 products. Thousands of clinics have received them and don't know whether to continue operating.
FDA rules on compounding, drug shortage designations, and prescribing authority are shifting constantly. Most providers have no guidance and no organized advocacy.
Manufacturers have enormous lobbying resources. Individual providers have none. Policy is being shaped entirely by the product side of this industry.
Without standardized protocols, every adverse event is a potential lawsuit. Most providers are operating on personal judgment with no documented standard of care.
Joining TAWLA is not just a directory listing. It is access to a comprehensive education, standards, and certification framework — built on an established national platform and launching at exactly the moment this industry needs it most.
Currently certified in GLP-1 & metabolic therapy, with recovery peptides, hormone optimization, and comprehensive weight management on our roadmap. Accurate credentials. Appropriate expertise.
Intake forms, dosing guidelines, monitoring cadences, adverse event procedures — ready to implement. Stop building alone.
Every FDA rule change and state law development translated into plain-language operational guidance. Never be blindsided again.
Your membership funds organized representation at the state and federal level — ensuring the clinical side of this industry has a voice in how policy is made.
Listed by specialty certification tier — currently GLP-1 & metabolic therapy, with additional categories on our roadmap — so patients and physicians find the right certified provider for their needs.
Thousands of providers just like you are waiting for exactly this. Be among the first certified members — establish your credentials, advance your practice, and help shape the future of obesity and peptide therapy care in America.
Medication access has outpaced clinical support across every distribution channel. TAWLA provides the education, standards, certification, and advocacy infrastructure that protects both patients and providers.
Best-practices frameworks for obesity and peptide therapies — intake, dosing, monitoring, adverse event management, and discontinuation — standardized across all provider types and medication categories.
Providers are certified in GLP-1 & metabolic therapy today, with recovery peptides, hormone optimization, and comprehensive weight management on our roadmap. Accurate matching. Appropriate expertise. Genuine patient safety.
The organized voice of the obesity and peptide therapy clinical community — engaging with manufacturers, discount platforms, regulators, and legislators to ensure provider interests shape policy.
Our certification and directory system helps patients find qualified, trained providers — and helps providers demonstrate their commitment to consistent, high-quality clinical care.
For discount platforms like Amazon, Cost Plus, and Trump RX — TAWLA certified providers offer fully outsourced clinical support for their customers, creating the clinical layer these platforms currently cannot provide.
A structured relationship between manufacturers, discount platforms, and the certified provider community — a pathway toward preferred supply arrangements, co-branded safety programs, and outsourced clinical support services.
When you choose a TAWLA-Certified provider, you're getting a clinical relationship built around your safety, your outcomes, and your long-term health — not just a prescription.
Thorough assessment of your health history, current conditions, and eligibility — including contraindication screening most sources skip entirely.
Required baseline labs including metabolic panel, HbA1c, thyroid, and lipids — the foundation for safe, monitored therapy from day one.
Titrated to your individual response, with structured escalation schedules and clear criteria for adjustment — not one-size-fits-all.
Regular check-ins, lab cadence, vital tracking, and patient-reported outcomes — so your provider can see how you're doing and adjust care accordingly.
A real clinical contact for questions, concerns, and side effects — not a chatbot. Someone who knows your case and can actually help.
Clear protocols for identifying, managing, and escalating side effects — including emergency care pathways for serious adverse events.
Certified providers integrate dietary guidance and lifestyle support into your treatment plan — because GLP-1 therapy works best as part of a comprehensive approach.
Structured maintenance protocols for when you reach your goal — because the objective is long-term health, not a quick fix.
Full disclosure of medication source, risks, alternatives, and expected outcomes before treatment begins.
Regular clinical check-ins and lab work — not just a subscription renewal and a shipment.
Transparency about where your medication originates and its quality verification process.
A responsive clinical team — not an automated system — available when questions or concerns arise.
A structured, supported process if therapy needs to be paused or stopped — no abrupt abandonment.
A safe, confidential pathway to report adverse events or concerns about the care you're receiving.
Whether you're a weight loss clinic in California, a medical spa in Texas, a telehealth platform nationwide, or a peptide therapy practice — TAWLA membership gives you the education, credentials, and collective strength you've been missing.
Certified Provider designation — the credential that shows regulators, attorneys, and patients you operate to a documented national standard
Complete clinical protocol library — intake forms, consent documents, dosing guidelines, monitoring cadences, adverse event procedures
Real-time regulatory updates — FDA guidance, state law changes, compounding regulations — all translated into clear operational guidance
National provider directory listing — the trusted destination where patients and physicians find certified GLP-1 providers
Training modules — keeping you and your team current on clinical best practices and regulatory developments
Peer network access — connect with thousands of providers navigating the same challenges
Collective advocacy representation — your practice's voice in policy discussions at state and federal levels
Not every provider is equally experienced in every medication category. Certification currently covers GLP-1 & metabolic therapy. Additional specialty tiers are on our roadmap, so patients and platforms can be matched with providers trained in the relevant therapy area — never a generic referral.
Developed from over 20 years of operational experience in physician-supervised weight loss care, currently undergoing formal clinical review — the definitive clinical best-practices framework for obesity and peptide therapy in America, supporting consistent, patient-centered care across all provider types.
This is fundamentally inconsistent with sound medical practice — and creates significant downstream cost exposure for every payer involved. TAWLA provides the solution.
What Payers Are Currently Funding Without Oversight
Payers cover the drug but not the clinical oversight ensuring it is being used safely, effectively, and at appropriate doses for each individual patient.
Without mandated provider monitoring, patients self-manage complex titration schedules, nutritional needs, and side effects — often unsuccessfully and at great personal risk.
Unmonitored adverse events — GI complications, muscle loss, nutritional deficiencies, cardiac issues — result in hospitalizations that cost payers far more than clinical oversight would have.
Without a clinical infrastructure requirement, payers have no visibility into whether the therapy they are funding is actually producing the health outcomes they are paying for.
How TAWLA Solves This for Payers
TAWLA certified providers give insurance companies, Medicare Advantage plans, and Medicaid managed care organizations a credentialed clinical network they can require, recommend, or reimburse — closing the oversight gap and reducing long-term costs.
TAWLA certified providers become the designated clinical support network for covered GLP-1 patients — ensuring every insured patient receives proper monitoring and follow-up.
TAWLA protocols provide the documented clinical framework giving payers confidence that covered therapy is being administered safely and consistently.
Aggregated, de-identified care data from the TAWLA network — subject to appropriate HIPAA and privacy frameworks — gives payers the outcomes visibility they currently cannot access.
A structured reimbursement arrangement for monitoring and follow-up services delivered through the certified provider network — funding the clinical infrastructure patients need.
Important: TAWLA is not a payer. It is the independent clinical standards organization whose certified provider network payers can designate, require, or reimburse to close the oversight gap they are currently funding.
Medicare & Medicare Advantage
Medicare Part D covers some GLP-1 medications for qualifying patients. Medicare Advantage plans are actively evaluating expanded coverage. Neither currently requires clinical monitoring as a coverage condition.
Medicaid Managed Care
Several state Medicaid programs and managed care organizations have begun covering GLP-1 therapy. These populations often have the fewest resources to self-manage complex medication regimens without support.
Private Insurance & Employer Plans
Large employers and private insurers covering GLP-1 therapy have a direct financial interest in ensuring those medications produce measurable health improvements — not just prescription fills.
You supply the medication. TAWLA provides the clinical support infrastructure your customers need and your platforms currently cannot offer. Together we create a complete, responsible patient care ecosystem — regardless of distribution channel.
The Problems You're Facing
Neither manufacturers nor discount platforms have any view into how patients are being monitored, what side effects are occurring, or what clinical outcomes look like across the independent provider channel.
Patients receiving medication through manufacturer direct programs or discount platforms have no organized clinical follow-up, monitoring, or side effect support — creating real patient safety gaps.
Adverse events in the independent channel — especially from improperly compounded or unsupported product — can reflect on brands whether or not they are directly involved.
For discount platforms, all competing primarily on price — offering clinical support services creates genuine loyalty, differentiation, and liability protection no competitor currently provides.
What TAWLA Offers You
Thousands of certified providers adhering to TAWLA clinical best-practice standards — educated on appropriate product sourcing, FDA-approved pathways, clinical monitoring, and patient support protocols.
Subject to appropriate HIPAA, privacy, consent, and de-identification frameworks — aggregated real-world care insights from across the certified provider network, available through formal data-sharing agreements.
For every patient receiving medication through your direct programs or platform — TAWLA certified providers serve as the clinical follow-up infrastructure currently missing from every channel.
Proactive partnership with an established national patient safety organization positions you as the responsible industry leader — ahead of anticipated FDA enforcement on compounding and unmonitored therapy.
You remain the product or distribution side. TAWLA is the independent, organized, credentialed clinical service side. Together, this creates the complete ecosystem patients need — with no exclusivity, no prescribing requirements, no referral fees, and no patient steering.
Certified TAWLA members receive structured access to manufacturer-sourced product — incentivizing migration away from compounders toward quality-controlled supply.
Co-branded patient education and monitoring initiatives — powerful public narrative and shared reputational benefit for both organizations.
TAWLA aggregates de-identified real-world outcomes data from the certified network — shared with manufacturer partners for research and regulatory work.
Every patient in your direct programs is connected to a TAWLA-certified provider for ongoing monitoring, support, and follow-up — the missing piece in your direct model.
A transparent, organized system for capturing and acting on safety signals — because the only way to improve safety is to actually measure it.
How It Works
Any adverse event, unexpected side effect, or quality concern submitted through the secure online portal.
Physician-led review within 48 hours — categorized by severity with appropriate response determined.
Certified providers receive direct outreach — guidance and protocol review — not punishment.
Serious adverse events escalated through established FDA MedWatch reporting channels.
Aggregated, de-identified safety data published annually — full transparency about what we're seeing and how the industry is improving.
All reports handled confidentially by the TAWLA Safety Committee. Anonymous submission accepted.
For patients, providers, and the public — the most comprehensive, clinically accurate GLP-1 education resource in the country.
A complete, plain-language guide — mechanism, benefits, risks, and what to expect.
How to maximize results and protect muscle mass while on GLP-1 medication.
What every GLP-1 patient should know — and the questions you should be asking.
Training covering pharmacology, indications, contraindications, and prescribing principles.
Current FDA guidance on GLP-1 compounding, the drug shortage designation, and what's changing.
Aggregated outcomes data from certified providers — the first national dataset of its kind.
The obesity and peptide therapy landscape is changing fast. The TAWLA Regulatory Watch newsletter delivers everything providers need — every week, in plain language.